Advanced Ovarian Cancer: Platinum resistant

(EPIK-O) A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer

Cancer Types: GYN, Ovarian

Lines of Therapy: 2nd Line Metastatic, 3rd Line+ Metastatic